Fundraising Fox
/People
Sign in

Dylan Morris

Investor

Managing Director at Insight Partners · Board director at Superluminal Medicines · Board director at ImmuneBridge · Board director at Averna Therapeutics

San Francisco Bay Area

Writes $10M – $350M checks · typically $25M

Find your path to Dylan

455 people in our graph can introduce you to Dylan.

Each arrow is one introduction. Sign up to fill in the first one.

Ask Tal Zaks to introduce you to Dylan

You →Tal · together at Averna Therapeutics (2024–2026) →Dylan

Ask Jamie Chen to introduce you to Dylan

You →Jamie · together at DEM Biopharma, Inc. →Dylan

Ask Sam Okafor to introduce you to Dylan

You →Sam · together at Gameto →Dylan

Sign up to find every way you can get introduced to Dylan

  • Your email: the people you already email who know Dylan
  • 2nd- and 3rd-degree connections: people you know who worked, studied or invested with Dylan
  • Your LinkedIn: the connections who can make the intro for you

We rank every route by how warm it is, so you raise on warm intros instead of cold emails.

Sign up with GoogleAlready have an account? Log in

About

Dylan Morris, a computational biologist who modeled immune cells across biochemistry and computer science, leads a software-first bio practice focused on computational biology, tech-enabled drug discovery and ending involuntary dying.

Likely email· guessed from name + firm domain, not firm-published

Invests in

AI & Machine LearningCybersecurityFintechFuture of WorkHealthtech

Board director at Superluminal Medicines

Intro paths

→

In turn, Dylan can intro founders to Superluminal Medicines's investors below.

Superluminal Medicines's investors · 4

GaingelsNew York · $200K – $500K checksInsight PartnersNew York · $120M – $350M checks · since 2023NVIDIASanta ClaraRA CapitalBoston · since 2025

Board director at ImmuneBridge

Intro paths

→

In turn, Dylan can intro founders to ImmuneBridge's investors below.

ImmuneBridge's investors · 8

GaingelsNew York · $200K – $500K checks · since 2023Healthspan CapitalOxford · $5K checks · since 2026Insight PartnersNew York · $120M – $350M checks · since 2023M VenturesLos Angeles · $10.8M checks · since 2023NFXSan Francisco · $250K – $5M checks · since 2025One Way VenturesNew York · $500K – $1.5M checks · since 2023PioneerToronto, OntarioSand Hill AngelsMenlo Park · $50K – $2M checks · since 2026

Co-founders at ImmuneBridge

PPPeretz Partensky
Peretz PartenskyExecutive Officer, Director

Board director at Averna Therapeutics

Intro paths

→

In turn, Dylan can intro founders to Averna Therapeutics's investors below.

Averna Therapeutics's investors · 4

Deep InsightTel AvivDelos CapitalCambridgeNovartis Venture FundBasel · $5M – $25M checks · since 2024OrbiMedNew York · $1M – $75M checks · since 2024

Experience

  1. Insight PartnersManaging Directorcurrent2021 — present
  2. PhaseVBoard Directorcurrent2025 — present
  3. Averna TherapeuticsBoard Directorcurrent2024 — present
  4. Superluminal Medicines Inc.Board Directorcurrent2023 — present
  5. ImmuneBridgeBoard Directorcurrent2023 — present
  6. Profluent BioBoard Directorcurrent2022 — present
  7. Unlearn.AIBoard Directorcurrent2022 — present
  8. DEM Biopharma, Inc.Board Directorcurrent2022 — present
  9. ArrePathBoard Directorcurrent2021 — present
  10. Switch TherapeuticsBoard Directorcurrent2020 — present
  11. Deciduous TherapeuticsBoard Directorcurrent2019 — present
  12. Exo TherapeuticsBoard Observercurrent2019 — present
  13. Dyno TherapeuticsBoard Directorcurrent2018 — present
  14. PlexiumBoard Observercurrent2018 — present
  15. GametoBoard Director2022 — 2024
  16. CRVGeneral Partner2017 — 2021
  17. Innovation EndeavorsInvestment Team2015 — 2017
  18. Integrated Plasmonics CorporationCo-Founder2011 — 2014

Skills & more

Entrepreneurship30R&D17Nanotechnology29Start-ups35Python8Biotechnology28Venture Capital6Biomedical Engineering5Science4Molecular Biology4Data Analysis2Mathematica1
+8 moreProduct DevelopmentMedical DevicesMatlabIntegrated MarketingBioinformaticsStrategyLifesciencesGenomics

From Dylan's professional profile.

Investments

Per curated public sources.

Colleagues at Insight Partners

Aayush Setty
Analyst at Insight Partners
Abdi Adan
Investor at Insight Partners
Adam Berger
Managing Director at Insight Partners
Adam Domingoes
Senior Associate at Insight Partners
Adam Vartabedian
Investor at Insight Partners
Aidan Waldman
Investor at Insight Partners
AJ Malhotra
Managing Director at Insight Partners
Ajay Gandhi
Investor at Insight Partners

Network7

Jeff HoringScout
Co-founder & Managing Director at Insight Partners
George MathewScout
Managing Director at Insight Partners
Hagi SchwartzScout
LP Advisory Board at Fusion VC
Aayush Setty
Analyst at Insight Partners
Abdi Adan
Investor at Insight Partners
Adam Berger
Managing Director at Insight Partners
Adam Domingoes
Senior Associate at Insight Partners

Investors connected to Dylan in public investor directories — a warm-intro map.

Frequently asked questions

Who is Dylan Morris?
Dylan Morris, a computational biologist who modeled immune cells across biochemistry and computer science, leads a software-first bio practice focused on computational biology, tech-enabled drug discovery and ending involuntary dying.
Where does Dylan Morris work?
Dylan Morris is Managing Director at Insight Partners and Board director at Superluminal Medicines and Board director at ImmuneBridge and Board director at Averna Therapeutics.
What does Dylan Morris invest in?
Dylan Morris invests in AI & Machine Learning, Cybersecurity, Fintech, Future of Work, Healthtech.
What check size does Dylan Morris write?
Dylan Morris typically writes checks of $10M – $350M.
What companies has Dylan Morris invested in?
Investments tracked here include Arrepath, Capacity Bio, DEM BioPharma, Dyno Therapeutics, Gameto, ImmuneBridge, PhaseV, Profluent Bio, Superluminal Medicines, Switch Therapeutics, Unlearn.AI.
Where did Dylan Morris go to school?
Dylan Morris studied at Caltech (Graduate Research, Biochemistry and Molecular Biophysics); Harvard University (AB, Computer Science).

Same school

Shared employers